Autism Pipeline Analysis Report 2025

As per the estimates from CDC's (Centers for Disease Control and Prevention) Autism and Developmental Disabilities Monitoring (ADDM) Network, around 1 in 36 children were reported to be identified with autism spectrum disorder. With the growing number of cases, there is a heightened focus on expediting the development of promising autism drugs and accelerating clinical trials. The autism pipeline analysis by the publisher includes major drugs currently under development. Moreover, rising public awareness and advocacy from autism organizations are also fueling the demand for advanced treatment options.

Report Coverage

The Autism Pipeline Analysis Report by the publisher gives comprehensive insights into autism therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for Autism. The autism report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The autism pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials including their adverse effects on patients suffering from the condition, and alignment with autism treatment guidelines to ensure optimal care practices.

The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to autism.

Autism Drug Pipeline Outlook

Autism or autism spectrum disorder (ASD) refers to a neurological and developmental disorders characterized by deficits in social communication and social interaction. Autistic individuals typically show inflexible, repetitive, and restricted patterns of interests, behaviors, and activities. Some people with autism can live independently whereas certain individuals may require life-long support and care.

Behavioral therapy is a widely used approach to improve social, communication, and learning skills in autistic people. For irritability and aggression, autism therapeutics include FDA-approved risperidone and aripiprazole for managing severe behavioral symptoms. Pharmaceutical companies are actively developing novel drug candidates such as gene and RNA-based therapies, cannabidiol (CBD), and oxytocin therapies. Additionally, the adoption of innovative technologies in drug development, along with adherence to autism treatment guidelines, is expected to improve patient outcomes and aid pipeline expansion in the near future.

Autism Epidemiology

According to the World Health Organisation (WHO), approximately 1 in 100 children are affected by autism, with the prevalence of the condition unknown in many low- and middle-income countries. On the other hand, the CDC's Autism and Developmental Disabilities Monitoring (ADDM) Network estimates that 1 in 36 children has been identified with autism.

Autism spectrum disorder is roughly 4 times more common in boys than in girls. It is reported to occur in all ethnic, racial, and socioeconomic groups.

Autism Pipeline Therapeutic Assessment

This section of the report covers the analysis of autism drug candidates based on several segmentations including:

By Phase

The pipeline assessment report covers 50+ drug analyses based on phase:

• Late-Stage Products (Phase 3 and Phase 4)
• Mid-Stage Products (Phase 2)
• Early-Stage Products (Phase I)
• Preclinical and Discovery Stage Products

By Drug Class

The pipeline assessment report covers 50+ drug analyses based on drug classes:

• Small Molecules
• Biologics
• Peptides
• Gene and RNA-based Therapies
• Natural Compounds and Cannabinoids

By Route of Administration

The autism report assessment covers 50+ drug analyses based on the route of administration.

• Oral
• Parenteral
• Others

Autism Pipeline Assessment Segmentation, By Phases

The report covers phase I, phase II, phase III, phase IV, and early phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to analysis, phase II covers a major share of the total clinical trials, with a substantial number of autism emerging drugs undergoing clinical development. Phase II holds the largest share at 50%, demonstrating strong progress in syphilis drug development. Phase I follows at 15%, reflecting early-stage advancements. Phase III also accounts for 15%, indicating promising late-stage trials. Phase IV contributes 5%, supporting post-market evaluation. Early Phase I at 3% highlights emerging innovations. These developments can drive market growth and improve treatment outcomes.

Autism Pipeline Assessment Segmentation, By Drug Classes

The drug molecule categories covered under the autism pipeline analysis include small molecules, biologics, peptides, gene and RNA-based therapies, and natural compounds and cannabinoids. The autism report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for autism. Endocannabinoid system modulators are emerging as a promising drug class in autism spectrum disorder (ASD) treatment. For instance, KT-20610, an orally administered therapy by Kingdom Therapeutics, is under investigation. It targets the gut-brain axis by modulating the endocannabinoid system, aiming to restore physiological balance and address core ASD symptoms while utilizing a delivery method that enhances bioavailability and reduces adverse effects.

Autism Clinical Trials Therapeutic Assessment - Competitive Dynamics

The report for the autism drug pipeline covers the profile of key companies involved in clinical trials and their drugs under development. It provides a detailed autism therapeutic assessment, analyzing the competitive dynamics of the clinical trial landscape. Below is the list of a few players involved in autism clinical trials:

• Curemark
• Aardvark Therapeutics, Inc.
• MapLight Therapeutics
• Intra-Cellular Therapies, Inc.
• Astrogen, Inc.
• ACADIA Pharmaceuticals Inc.
• AbbVie

Autism Emerging Drugs Profile

This section covers the detailed analysis of each drug under multiple phases, including phase I, phase II, phase III, phase IV, and emerging drugs for vitiligo. It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of autism drug candidates.

Drug: AST-001

Sponsored by Astrogen, Inc., the objective of this randomized, double-blinded, multicenter clinical trial is to investigate the efficacy and safety of AST-001 in children with autism spectrum disorder. The study is under Phase III clinical development and has an estimated 160 participants.

Drug: CM-AT

Curemark is conducting a Phase III open-label extension study aimed at examining the efficacy and safety of autism drug candidate CM-AT in treating autism with all levels of fecal chymotrypsin. The interventional study has enrolled about 405 children and is expected to be completed by January 2025.

Key Questions Answered in the Autism Pipeline Analysis Report

• Which companies/institutions are leading the autism drug development?
• What is the efficacy and safety profile of autism pipeline drugs?
• Which company is leading the autism pipeline development activities?
• What is the current autism commercial assessment?
• What are the opportunities and challenges present in the autism pipeline landscape?
• What is the efficacy and safety profile of autism pipeline drugs?
• Which company is conducting major trials for autism drugs?
• Which companies/institutions are involved in autism collaborations aimed at providing enhanced therapeutic alternatives for patients?
• What are the geographies covered for clinical trials in autism?

Reasons To Buy This Report

The Autism Pipeline Analysis Report provides a strategic overview of the latest and future landscape of treatments for autism. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into market trends, regulatory environments, and potential growth opportunities within autism pipeline insights.

This product will be delivered within 3-5 business days.